Feasibility of Low-Dose Interleukin-2 Therapy Following T-Cell-Depleted Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Matched or -Mismatched Family Member Donors

Natural Killer Cell-Enriched Donor Lymphocyte Infusions from A 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation

(2010) David A. Rizzieri et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia

(2010) Jeffrey E. Rubnitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438)

(2008) J. A. Thompson et al.   BLOOD

Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3–6/6 HLA matched donors

(2008) D A Rizzieri et al.   BONE MARROW TRANSPLANTATION

A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation

(2008) K-Y Liu et al.   BONE MARROW TRANSPLANTATION

The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease

(2008) E. M. Dunbar et al.   HAEMATOLOGICA